Overview of benefit/risk of biological agents

Clinical and Experimental Rheumatology

Volumn 22, Issue 5 SUPPL. 35, 2004, Pages

  Imperato, Anna K ^b   Bingham III, Clifton O ^b   Abramson, Steven B ^a  

^a NYU HOSPITAL FOR JOINT DISEASES   (United States)

^b NONE

Author keywords

Demyelination; Drug induced lupus; Heart failure; Infections; Lymphoma; Rheumatoid arthritis; TNF antagonists

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; ETANERCEPT; INFLIXIMAB; ISONIAZID; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; ANAKINRA; ANTI DOUBLE STRANDED DNA ANTIBODY; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; BIOLOGICAL PRODUCT; C REACTIVE PROTEIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOGLOBULIN M ANTIBODY; RECOMBINANT TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ABSCESS; ASPERGILLUS FUMIGATUS; BACTERIAL ARTHRITIS; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; BARTONELLA; BLADDER DISEASE; BRAIN ABSCESS; BRUCELLA; BRUCELLOSIS; CANDIDA; CANDIDIASIS; CENTRAL NERVOUS SYSTEM INFECTION; CHOLECYSTITIS; CLINICAL TRIAL; COCCIDIOIDOMYCOSIS; CONGESTIVE HEART FAILURE; COXITIS; CRYPTOCOCCOSIS; CRYPTOCOCCUS; CYTOMEGALOVIRUS INFECTION; DEMYELINATING DISEASE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; ESOPHAGITIS; EXTRAPULMONARY TUBERCULOSIS; HEART FAILURE; HEPATOSPLENOMEGALY; HISTOPLASMA CAPSULATUM; HISTOPLASMOSIS; HUMAN; INTERSTITIAL PNEUMONIA; INTESTINE TUBERCULOSIS; LEUKEMIA; LISTERIA MONOCYTOGENES; LISTERIOSIS; LUNG ASPERGILLOSIS; LUNG TUBERCULOSIS; LYMPHOMA; MENINGOENCEPHALITIS; MILIARY TUBERCULOSIS; MULTIPLE SCLEROSIS; MYCOBACTERIUM TUBERCULOSIS; MYCOSIS; NOCARDIA; NOCARDIOSIS; OPPORTUNISTIC INFECTION; OSTEOMYELITIS; PANCYTOPENIA; PNEUMOCYSTOSIS; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; RHEUMATOID ARTHRITIS; RICKETTSIOSIS; RISK BENEFIT ANALYSIS; SALMONELLA; SALMONELLOSIS; SEPSIS; SEPTICEMIA; SPOROTRICHOSIS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS GROUP A; STREPTOCOCCUS INFECTION; SYNOVITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TONSIL DISEASE; TOXOPLASMA; TOXOPLASMOSIS; TUBERCULOSIS; TUBERCULOUS LYMPHADENITIS; TUBERCULOUS MENINGITIS; TUBERCULOUS OSTEOMYELITIS; TUBERCULOUS PERITONITIS; TUBERCULOUS PLEURISY; TUBERCULOUS SPONDYLITIS; UROGENITAL TUBERCULOSIS; VIRUS MYOCARDITIS; ARTICLE; DRUG MARKETING; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; INFECTION SENSITIVITY; LEUKOENCEPHALOPATHY; LUPUS LIKE SYNDROME; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); TUBERCULIN TEST;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; INCIDENCE; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOMA; OPPORTUNISTIC INFECTIONS; RISK ASSESSMENT; SIALOGLYCOPROTEINS;

EID: 4944234410     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. RUDERMAN EM, MARKENSON JA: Granulomatous infections and tumor necrosis factor antagonist (abstract). Arthritis Rheum 2003; 48 (Suppl. 9): S541.
2. US Food and Drug Administration:. Arthritis Advisory Committee March 4, 2003. Update on the TNF-α Blocking Agents. Available at www.fda.gov/ohrms/dockets/ac/03/briefing/3930B1_01_B-TNF. Briefing.htm. Accessed November 11, 2003.
3. BIEBER J, KAVANAUGH A: Tuberculosis and opportunistic infections: relevance to biologic agents. Clin Exp Rheumatol 2004; 22 (Suppl. 35): S127-S133.
4. MAGNANO M, ROBINSON WH, GENOVESE MC: Demyelination and the use of TNF inhibition. Clin Exp Rheumatol 2004; 22 (Suppl. 35): S132-S140.
5. VAN Vollenhoven RF: Benefits and risks of biological agents: lymphomas. Clin Exp Rheumatol 2004; 22 (Suppl. 35): xx-xx.
6. CUSH JJ: Unusual toxicities with TNF inhibition: heart failure and drug-induced lupus. Clin Exp Rheumatol 2004; 22 (Suppl. 35): S141-S147.
7. ELLERIN T, RUBIN RH, WEINBLATT ME: Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum 2003; 48: 3013-22.
8. CUSH J: Etanercept (Enbrel) Label Updated Following Post-marketing Infectious Events. ACR hotline '99. Available at www.rheumatology.org/publications/hotline/archive/ 0799adverse.asp?aud=mem. Accessed December 3, 2003.
9. CUNNANE G, DORAN M, BRESNIHAN B: Infections and biological therapy in RA [Review]. Best Pract Res Clin Rheumatol 2003; 17: 345-63.
10. MOHAN AK, COTE TR, SIEGEL JN, BRAUN MM: Infectious complications of biologic treatments of RA [Review]. Curr Opin Rheumatol 2003; 15: 179-84.
11. WALLIS RS, BRODER MS, WONG JY et al.: Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004; 38: 1261-5.
12. COYLE CM, WEISS LM, RHODES LV 3rd et al.: Fatal myositis due to the microsporidian Brachiola algerae, a mosquito pathogen. N Engl J Med 2004; 351: 42-7.
13. US Food and Drug Administration: Safety Update on TNF-α Antagonists: Infliximab and Etanercept. Available at www.fda.gov/ohrms/dockets/ac/01/briefing/ 3779b2_01_cber_safety%20_revision2.pdf. Accessed November 11, 2003.
14. CANNON GW, STRAND V, SCARAZZINI L et al.: Comparison of adverse event reporting rates for etanercept, infliximab, leflunomide and methotrexate (abstract). Arthritis Rheum 2003; 48 (Suppl. 9): S542.
15. KEANE J, GERSHON S, WISE RP et al.: Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing gent. N Engl J Med 2001; 345: 1098-104.
16. MANADAN AM, MOHAN AK, COTE TR et al.: Tuberculosis and etanercept treatment (abstract). Arthritis Rheum 2002; 46 (Suppl. 9): S356.
17. CARMONA L, HERNANDEZ-GARCIA C, VADILLO C et al.: EMECAR Study Group. Increased risk of tuberculosis in patients with RA. J Rheumatol 2003; 30: 1436-9.
18. GARDAM M, IVERSON K: Rheumatoid arthritis and tuberculosis: time to take notice. J Rheumatol 2003; 30: 1397-9.
19. FURST DE, CUSH J, KAUFMANN S et al.: Preliminary guidelines for diagnosing and treating tuberculosis in patients with rheumatoid arthritis in immunosuppressive trials or being treated with biological agents. Ann Rheum Dis 2002; 61: 62ii-63ii.
20. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167: 603-62.
21. GARDAM MA, KEYSTONE EC, MENZIES R et al.: Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003; 3: 148-55.
22. CURTIS J, SHATIN D, RAWSON NSB et al.: Impact of risk communication on tuberculin skin testing for infliximab and etanercept users (abstract). Arthritis Rheum 2003; 48 (Suppl. 9): S1584.
23. BAETEN D, KRUITHOF E, VAN DEN BOSCH F et al.: Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? Ann Rheum Dis 2003; 62: 829-34.
24. BONILLA G, FERNANDEZ-MELÓN J, GARCIA-APARICIO A et al.: Incidence of latent tuberculosis in patients of our unit before receiving treatment with anti-TNF (abstract). Arthritis Rheum 2003; 48 (Suppl. 9): S1341.
25. RUIZ JP, CENTENO NO, ALVAREZ ER: Development of tuberculosis in a patient treated with infliximab who had received prophylactic therapy with isoniazid. J Rheumatol 2003; 30: 1657-8.
26. VAN DER KLOOSTER JM, BOSMAN RJ, OUDEMANS-VAN STRAATEN HM et al.: Disseminated tuberculosis, pulmonary aspergillosis and cutaneous herpes simplex infection in a patient with infliximab and methotrexate. Intensive Care Med 2003; 29: 2327-9.
27. SLIFMAN NR, GERSHON SK, LEE JH et al.: Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum 2003; 48: 319-24.
28. LEE JH, SLIFMAN NR, GERSHON SK et al.: Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor-α antagonists infliximab and etanercept. Arthritis Rheum 2002; 46: 2565-70.
29. ACR Hotline: FluMist(r)Nasal Spray Influenza Vaccine: Implications for Rheumatology. Available at www.rheumatology.org/publications/hotline/1003bflu.asp. Accessed December 3, 2003.
30. GLUCK T, LINDE HJ, SCHOLMERICH J et al.: Anti-tumor necrosis factor therapy and Listeria monocytogenes infection: report of two cases. Arthritis Rheum 2002; 46: 2255-7.
31. GOTTLIEB GS, LESSER CF, HOLMES KK et al.: Disseminated sporotrichosis associated with treatment with immunosuppressants and tumor necrosis factor-α antagonists. Clin Infect Dis 2003; 37:838-840.
32. WOOD KL, HAGE CA, KNOX KS et al.: Histoplasmosis after treatment with anti-tumor necrosis factor-α therapy. Am J Respir Crit Care Med 2003; 167: 1279-82.
33. BOTHA T, RYFFEL B: Reactivation of latent tuberculosis infection in TNF-deficient mice. J Immunol 2003; 171: 3110-8.
34. ROACH DR, BEAN AG, DEMANGEL C et al.: TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol 2002; 168: 4620-7.
35. LOCKSLEY RM, KILLEEN N, LENARDO MJ: The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001; 104: 487-501.
36. KROESEN S, WIDMER AF, TYNDALL A et al.: Serious bacterial infections in patients with RA under anti-TNF-alpha therapy. Rheumatology 2003; 42: 617-21.
37. ELWOOD RL, PELSZYNSKI MM, CORMAN LI: Multifocal septic arthritis and osteomyelitis caused by group A Streptococcus in a patient receiving immunomodulating therapy with etanercept. Pediatr Infect Dis J 2003; 22: 286-8.
38. AMITAL H, AAMAR S, RUBINOW A: Bilateral septic arthritis of the hip: does etanercept play a role? A case report. J Bone Joint Surg Am 2003; 85A: 2205-6.
39. KELLEY JT, CONN DL: Perioperative Management of the Rheumatic Disease Patient. Bulletin on the Rheumatic Diseases. For Evidence-Based Management of Rheumatic Diseases. Available at www.arthritis.org/research/bulletin/vol51no6/51_6_Medications.asp. Accessed Dec 1, 2003.
40. ROSANDICH PA, KELLEY JT 3rd, CONN DL: Perioperative management of patients with rheumatoid arthritis in the era of biologic response modifiers. Curr Opin Rheumatol 2004; 16: 192-8.
41. WATTERSON MK, ARROWSMITH ER, COFFEY CS et al.: Population-based study of methotrexate use and risk of lymphoma in patients with RA (abstract). Arthritis Rheum 2002; 46 (Suppl. 9):S1204.
42. PRIOR P, SYMMONS DP, HAWKINS CF et al.: Cancer morbidity in RA. Ann Rheum Dis 1984; 43: 128-31.
43. EKSTROM K, HJALGRIM H, BRANDT L et al.: Risk of malignant lymphomas in patients with RA and in their first-degree relatives. Arthritis Rheum 2003; 48: 963-70.
44. BAECKLUND E, EKBOM A, SPAREN P et al.: Disease activity and risk of lymphoma in patients with RA: nested case-control study. BMJ 1998; 317: 180-1.
45. WOLFE F, MITCHELL DM, SIBLEY JT et al.: The mortality of RA. Arthritis Rheum 1994; 37: 481-94.
46. CIBERE J, SIBLEY J, HAGA M: RA and the risk of malignancy. Arthritis Rheum 1997; 40: 1580-6.
47. MELLEMKJAER L, LINET MS, GRIDLEY G et al.: RA and cancer risk. Eur J Cancer 1996; 32A: 1753-7.
48. WOLFE F, MICHAUD K: Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 50: 1740-51.
49. SILMAN AJ, PETRIE J, HAZLEMAN B et al.: Lymphoproliferative cancer and other malignancy in patients with RA treated with azathioprine: a 20 year follow up study. Ann Rheum Dis 1988; 47: 988-992.
50. GEORGESCU L, PAGET SA: Lymphoma in patients with RA: what is the evidence of a link with methotrexate? Drug Saf 1999; 20: 475-87.
51. BROWN SL, GREENE MH, GERSHON SK et al.: Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002; 46: 3151-8.
52. United States Department of Health and Hyman Services Centers for Disease Control and Prevention: United Stales Cancer Statistics 2000 Incidence Report. p21, 23. Available at: www.cdc.gov/cancer/npcr/uscs/2000/index.htm. Accessed October 29, 2003.
53. WOLFE F, FRIES JF: Rate of death due to leukemia/lymphoma in patients with RA. Arthritis Rheum 2003; 48: 2694-5.
54. MOHAN AK, EDWARDS ET, COTE TR et al.: Drug-induced systemic lupus erythematosus and TNF-alpha blockers. Lancet 2002; 360: 646.
55. CAIRNS AP, DUNCAN MK, HINDER AE et al.: New onset systemic lupus erythematosus in a patient receiving etanercept for RA. Ann Rheum Dis 2002; 61: 1031-2.
56. DEBANDT M, VITTECOQ O, DESCAMPS V et al.: Anti-TNF-alpha-induced systemic lupus syndrome. Clin Rheumatol 2003; 22: 56-61.
57. CHARLES PJ, SMEENK RJ, De JONG J et al.: Assessment of antibodies to double-stranded DNA induced in RA patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 2000; 43: 2383-90.
58. SHAKOOR N, MICHALSKA M, HARRIS CA et al.: Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002; 359: 579-80.
59. KWON HJ, COTE TR, CUFFE MS et al.: Case reports of heart failure after therapy with a tumor necrosis factor-α antagonist. Ann Intern Med 2003; 138: 807-11.
60. WOLFE F, MICHAUD K: Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med 2004; 116: 305-11.
61. PEARCE BD, HOBBS MV, McGRAW TS et al.: Cytokine induction during T-cell mediated clearance of mouse hepatitis virus from neurons in vivo. J Virol 1994; 68: 5483-95.
62. RUBY J, BLUETHMANN H, PESCHON JJ: Antiviral activity of tumor necrosis factor (TNF) is mediated via p55 and p75 TNF receptors. J Exp Med 1997; 186: 1591-6.
63. MANN DL: Tumor necrosis factor and viral myocarditis: the fine line between innate and inappropriate immune responses in the heart. Circulation 2001; 103: 626-9.
64. WADA H, SAITO K, KANDA T et al.: Tumor necrosis factor-alpha (TNF-α) plays a protective role in acute viral myocarditis in mice: A study using mice lacking TNF-alpha. Circulation 2001; 103: 743-9.
65. MOHAN N, EDWARDS ET, CUPPS TR et al.: Demyelination occurring during anti-tumor necrosis factor α therapy for inflammatory arthritides. Arthritis Rheum 2001; 44: 2862-69.
66. NINDS: NINDS Progressive Multifocal Leukoencephalopathy Information Page: Available at www.ninds.nih.gov/health∠d⋯dical/disorders/pml_doc.htm. Accessed December 1, 2003.
67. CHUKWUDELUNZU F: Case report: progressive multifocal leukoencephalopathy as an initial manifestation of AIDS. Hosp Physician 2001.
68. TYLER KL: Viral meningitis and encephalitis. In BRAUNWALD E, FAUCI AS and ISSELBACHER KJ et al. (Eds.): Harrison's Principles of Internal Medicine, 15th ed. McGraw-Hill; 2001-2003. Also available at: (http://80-harrisons.accessmedicine.com.ezproxy.med.nyu.edu/ server-java/Arknoid/amed/harrisons/co_chapters/ch373/ch373_p13.html. Accessed December 1,2003.
69. DEMETER L: JC, BK, and other polyomaviruses: Progressive multifocal leukoencephalopathy. In MANDELL G, BENNETT J and DOLIN R (Eds.): Principles and Practice of Infectious Diseases, 5th ed. Florida, Churchill Livingstone 2000: 1645-9.
70. Amgen, Etanercept Safety Review. Food and Drug Administration. Arthritis and Advisory Committee. Slides. Available at www.fda.gov/ohrms/dockets/ac/03/slides/3930s1.htm. Accessed November 7, 2003.
71. BARR SG, MARTIN L, CHUNG C, MAKSYMOWYCH WP: Mandatory pharmacosurveillance - A Canadian model for access to therapy and research. Clin Exp Rheumatol 2004; 22 (Suppl. 35): S39-S43.